Format

Send to

Choose Destination
J Vasc Surg. 2019 Feb;69(2):507-515. doi: 10.1016/j.jvs.2018.04.068.

A randomized trial of vonapanitase (PATENCY-1) to promote radiocephalic fistula patency and use for hemodialysis.

Author information

1
Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC. Electronic address: ableyer@wakehealth.edu.
2
Cardiovascular and Thoracic Surgery, Lutheran Medical Group, Fort Wayne, Ind.
3
Vascular Surgery, University of California Irvine, Orange, Calif.
4
General Surgery, Sharp Healthcare, San Diego, Calif.
5
Lake Washington Vascular Surgeons, Bellevue, Wash.
6
Vascular Surgery, Brigham and Women's Hospital, Boston, Mass.
7
Department of Medicine, University of Alabama at Birmingham, Birmingham, Ala.
8
Cardiovascular Surgery, The Methodist Hospital, Houston, Tex.
9
Department of Medicine, University of Iowa, Iowa City, Iowa.
10
Arizona Kidney Disease & Hypertension Centers, Phoenix, Ariz.
11
Surgery Division, RenalCare Associates, Peoria, Ill.
12
Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC.
13
Proteon Therapeutics, Waltham, Mass.

Erratum in

Abstract

OBJECTIVE:

Arteriovenous fistulas created in patients with chronic kidney disease often lose patency and fail to become usable. This prospective trial evaluated the efficacy of vonapanitase, a recombinant human elastase, in promoting radiocephalic fistula patency and use for hemodialysis.

METHODS:

PATENCY-1 was a double-blind, placebo-controlled trial that enrolled 349 patients on or approaching hemodialysis and being evaluated for radiocephalic arteriovenous fistula creation. Of these, 313 were randomized and 311 treated. Patients were assigned to vonapanitase (n = 210) or placebo (n = 103). The study drug solution was applied topically to the artery and vein for 10 minutes immediately after fistula creation. The primary and secondary end points were primary patency (time to first thrombosis or corrective procedure) and secondary patency (time to abandonment). Tertiary end points included use of the fistula for hemodialysis, fistula maturation by ultrasound, and procedure rates.

RESULTS:

The Kaplan-Meier estimates of 12-month primary patency were 42% (95% confidence interval [CI], 35-49) and 31% (95% CI, 21-42) for vonapanitase and placebo (P = .25). The Kaplan-Meier estimates of 12-month secondary patency were 74% (95% CI, 68-80) and 61% (95% CI, 51-71) for vonapanitase and placebo (P = .048). The proportions of vonapanitase and placebo patients were 39% and 25% (P = .035) with unassisted use for hemodialysis and 64% and 44% (P = .006) with unassisted plus assisted use.

CONCLUSIONS:

Vonapanitase treatment did not significantly improve primary patency but was associated with increased secondary patency and use for hemodialysis. Further research is needed to evaluate these end points.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02110901.

KEYWORDS:

Fistula; Hemodialysis access; Radiocephalic; Randomized, clinical trial; Vonapanitase

Comment in

PMID:
30683197
DOI:
10.1016/j.jvs.2018.04.068
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center